We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.39 | -1.31% | 29.36 | 29.36 | 29.38 | 29.73 | 29.20 | 29.71 | 6,192,629 | 20:07:50 |
From May 2019 to May 2024
By Michael Dabaie
PTC Therapeutics Inc. said Wednesday Evrysdi was approved in Brazil by the National Health Surveillance Agency for the treatment of spinal muscular atrophy.
PTC said the approval was obtained within seven months of Roche's initial submission and marks the second country to approve Evrysdi. Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics.
Additionally, PTC said a new drug application was filed for Evrysdi for the treatment of SMA with the Japanese Ministry of Health, Labor and Welfare. The filing in Japan by Chugai Pharmaceutical Co. Ltd., part of the Roche group, triggers a $7.5 million milestone payment to PTC from Roche.
Spinal muscular atrophy is a severe, progressive neuromuscular disease that can be fatal.
The U.S. Food and Drug Administration approved Evrysdi in August. Evrysdi is marketed in the U.S. by Roche's Genentech.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
October 21, 2020 09:21 ET (13:21 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
